Under the deal, Accenture will provide digital data integration services to Roche's NAVIFY Tumor Board solution.
Senseonics, TypeZero and Roche Diabetes Care team-up to trial a long-term artificial pancreas system
The trial will integrate Senseonics' Eversense CGM System with TypeZero's inControl AP algorithms and Roche's Accu-Chek Insight Insulin Pump.
The idea is to make mySugr an integral part of Roche's new patient-centered digital health services platform in diabetes care.
Users will benefit from enhanced capabilities to share diabetes data with their healthcare providers and caregivers.
Vivonoetics, in partnership with Great Lakes NeuroTechnologies, will be providing advanced respiratory assessment to the Roche FIREFISH study.
Under the deal, registered users of the mySugr app will get the ability to automatically upload blood glucose data from the Accu-Chek Connect meter.
Said therapy will be evaluated in a clinical trial in France, and will involve an app and telemedicine services to monitor patients between doctor visits.
The app is made to complement the traditional physician-led assessments with automated tests that continuously measure their symptom fluctuations.
The two parties aim to advance chronic care management using connected therapy to further improve quality, increase convenience and drive patient engagement.
The company will be integrated into the Roche Sequencing Unit, and will continue to focus on development of their genomic analysis solution.